Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations

被引：11

作者：

Jain, Nitin ^{[1
]}

Thompson, Philip A. ^{[1
]}

Burger, Jan A. ^{[1
]}

Ferrajoli, Alessandra ^{[1
]}

Borthakur, Gautam ^{[2
]}

Bose, Prithviraj ^{[1
]}

Estrov, Zeev E. ^{[1
]}

Kadia, Tapan M. ^{[1
]}

Takahashi, Koichi ^{[1
]}

Garg, Naveen ^{[3
]}

Wang, Xuemei ^{[4
]}

Kanagal-Shamanna, Rashmi ^{[5
]}

Patel, Keyur ^{[5
]}

Lopez, Wanda ^{[1
]}

Ayala, Ana ^{[1
]}

Plunkett, William ^{[6
]}

Gandhi, Varsha ^{[6
]}

Kantarjian, Hagop M. ^{[1
]}

O'Brien, Susan M. ^{[7
]}

Keating, Michael J. ^{[1
]}

Wierda, William G. ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[2] Univ Texas MD Anderson Canc Ctr, Sect Mol Hematol & Therapy, Dept Leukemia, Houston, TX 77030 USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Diagnost Radiol, Houston, TX 77030 USA

[4] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA

[5] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA

[6] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA

[7] Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Irvine, CA USA

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-185

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

695

引用

页数：4

共 50 条

[31] TP53 codon 72 polymorphism in patients with chronic lymphocytic leukaemia: identification of a subgroup with mutated IGHV genes and poor clinical outcome
Majid, Aneela
Richards, Tom
Dusanjh, Palminder
Kennedy, D. Benjamin J.
Miall, Fiona
Gesk, Stefan
Siebert, Reiner
Wagner, Simon D.
Dyer, Martin J. S.
BRITISH JOURNAL OF HAEMATOLOGY, 2011, 153 (04) : 533 - 535
[32] Retrospective Real-Life Comparison of Obinutuzumab Plus Chlorambucil Versus Ibrutinib in Previously Untreated and Unfit Patients with Chronic Lymphocytic Leukemia without TP53 Disruptions. Interim Results from the Italian CLL Campus
Visentin, Andrea
Mauro, Francesca Romana
Pietrasanta, Daniela
Fresa, Alberto
Vitale, Candida
Ciolli, Stefania
Cassin, Ramona
Cibien, Francesca
Sportoletti, Paolo
Gentile, Massimo
Rigolin, Gian Matteo
Quaglia, Francesca M.
Murru, Roberta
Gozzetti, Alessandro
Molica, Stefano
Marchetti, Monia
Scarfo, Lydia
Reda, Gianluigi
Coscia, Marta
Laurenti, Luca
Pizzolo, Giovanni
Semenzato, Gianpietro
Foa, Robin
Cuneo, Antonio
Trentin, Livio
BLOOD, 2020, 136
[33] Long-Term Efficacy of First-Line Ibrutinib Treatment for Chronic Lymphocytic Leukemia (CLL) With 4 Years of Follow-Up in Patients With TP53 Aberrations (del(17p) or TP53 Mutation): A Pooled Analysis From 4 Clinical Trials
Allan, John N.
Shanafelt, Tait
Wiestner, Adrian
Moreno, Carol
O'Brien, Susan M.
Braggio, Esteban
Liu, Emily
Dean, James P.
Lai, Dominic
Ahn, Inhye E.
BLOOD, 2020, 136
[34] Final Analysis of the Prospective Multicenter CLL2-Give Trial of Obinutuzumab (GA101, G), Ibrutinib (I), and Venetoclax (Ve) in Untreated Patients with CLL with 17p Deletion/TP53 Mutation
Huber, Henriette
Tausch, Eugen
Schneider, Christof
Edenhofer, Simone
Von Tresckow, Julia
Robrecht, Sandra
Giza, Adam
Zhang, Can
Furstenau, Moritz
Dreger, Peter
Ritgen, Matthias
Illmer, Thomas
Illert, Anna Lena
Duerig, Jan
Boettcher, Sebastian
Niemann, Carsten Utoft
Kneba, Michael
Fink, Anna-Maria
Fischer, Kirsten
Doehner, Hartmut
Hallek, Michael
Eichhorst, Barbara
Stilgenbauer, Stephan
BLOOD, 2022, 140
[35] Final Analysis of the Prospective Multicenter CLL2- GIVe Trial of Obinutuzumab (GA101, G), Ibrutinib (I), and Venetoclax (Ve) in Untreated Patients with CLL with 17p Deletion/TP53 Mutation
Huber, H.
Edenhofer, S.
von, Tresckow J.
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (02) : 9 - 10
[36] Entinostat combined with Fludarabine synergistically enhances the induction of apoptosis in TP53 mutated CLL cells via the HDAC1/HO-1 pathway
Zhou, Zhen
Fang, Qin
Li, Peifan
Ma, Dan
Zhe, Nana
Ren, Mei
Chen, Bingqing
He, Zhengchang
Wang, Jun
Zhong, Qin
Wang, Jishi
LIFE SCIENCES, 2019, 232
[37] CRISTALLO: Results from a Phase III Trial of Venetoclax-Obinutuzumab Versus Fludarabine, Cyclophosphamide and Rituximab or Bendamustine-Rituximab in Patients with Untreated Chronic Lymphocytic Leukemia without Del(17p) or TP53 Mutations
Sharman, Jeff P.
Laurenti, Luca
Ferrant, Emmanuelle
Montero, Luis Felipe Casado
Mulligan, Stephen P.
Harrup, Rosemary
Opat, Stephen
Ibatici, Adalberto
Marasca, Roberto
Sportoletti, Paolo
Lefebure, Marcus
Boyer, Michelle
Jiang, Yanwen
Barlera, Simona
Cazares, Oscar
Morschhauser, Franck
BLOOD, 2024, 144 : 3237 - 3238
[38] Mutational Status of the TP53 Gene as a Predictor of Response and Survival in CLL Patients with and without 17p Deletion
Gonzalez, David
Martinez, Pilar
Wade, Rachel
Hockley, Sarah Lorna
Brito-Babapulle, Vasantha
Oscier, David Graham
Matutes, Estelia
Dearden, Claire E.
Richards, Sue
Catovsky, Daniel
Morgan, Gareth J.
BLOOD, 2008, 112 (11) : 291 - 291
[39] Role of TP53 mutations in predicting response to TKI treatment in EGFR-mutated NSCLC patients.
Ulivi, Paola
Canale, Matteo
Petracci, Elisabetta
Chiadini, Elisa
Dazzi, Claudio
Capelli, Laura
Gamboni, Alessandro
Casanova, Claudia
Papi, Maximilian
Mariotti, Marita
De Luigi, Nicoletta
Burgio, Marco Angelo
Ludovini, Vienna
Bennati, Chiara
Chiari, Rita
Calistri, Daniele
Crino, Lucio
Amadori, Dino
Delmonte, Angelo
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[40] PREDICTIVE AND PROGNOSTIC IMPACT OF GENE MUTATIONS IN THE CONTEXT OF FLUDARABINE AND CYCLOPHOSPHAMIDE WITH OR WITHOUT OFATUMUMAB TREATMENT IN PATIENTS WITH REL/REF CLL
Tausch, E.
Dolnik, A.
Estenfelder, S.
Opatrna, V.
Blaette, T.
McKeown, A.
Robak, T.
Grosicki, S.
Pallaud, C.
Mertens, D.
Bullinger, L.
Doehner, H.
Stilgenbauer, S.
HAEMATOLOGICA, 2017, 102 : 70 - 71

← 1 2 3 4 5 →